Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.13 - Radiology/Staging/Screening
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiology/Staging/Screening
-
+
P1.13-007 - Is Central Lung Tumor Location Really Predictive for Occult Mediastinal Nodal Disease in (Suspected) NSCLC Staged cN0 on PET-CT?
09:30 - 09:30 | Presenter: Herbert Decaluwe | Author(s): J. Moons, W. De Wever, C. Deroose, A. Stanzi, L. Depypere, K. Nackaerts, J. Coolen, M. Lambrecht, Dirk K De Ruysscher, Johan F. Vansteenkiste, D. Van Raemdonck, Paul De Leyn, C. Dooms
- Abstract
Loading...
-
+
OA 05 - Next Generation TKI
- 15:45 - 17:30
- 10/16/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Advanced NSCLC
- Moderators:James Chih-Hsin Yang, Fiona Blackhall
-
+
OA 05.02 - Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
15:55 - 16:05 | Presenter: Jhanelle Elaine Gray | Author(s): Isamu Okamoto, V. Sriuranpong, Johan F. Vansteenkiste, F. Imamura, J.S. Lee, Y. Pang, M. Cobo, K. Kasahara, R. Hodge, Brian B Lentrichia, S. Dearden, Suresh S Ramalingam
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf | Author(s): Ji-Youn Han, Makoto Nishio, P. Souquet, Luis Paz-Ares, F. De Marinis, Takashi Seto, M. De Jonge, T.M. Kim, Johan F. Vansteenkiste, Daniel SW Tan, Edward Brian Garon, H.J. Groen, Maximilian Johannes Hochmair, Enriqueta Felip, Noemi Reguart, M. Thomas, T.R. Overbeck, K. Ohashi, M. Giovannini, R. Yura, A. Joshi, M. Akimov, R. Heist
- Abstract
Loading... -
+
P2.04-013 - ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
09:30 - 09:30 | Presenter: Enriqueta Felip | Author(s): Johan F. Vansteenkiste, Frances A Shepherd, Luis Paz-Ares, Fabrice Barlesi, S. Burgers, C. Cai, F. Kiertsman, J. Scott, T. McCulloch, Y.Y. Lau, D. Morgensztern
- Abstract
Loading...
-
+
MA 10 - Immunotherapy I
- 11:00 - 12:30
- 10/17/2017
- Location: Room 303 + 304
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Moderators:S. Wang, Robert Pirker
-
+
MA 10.03 - 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)
11:10 - 11:15 | Presenter: Keunchil Park | Author(s): C. Lewanski, Shirish M Gadgeel, L. Fehrenbacher, Julien Mazieres, A. Rittmeyer, Ji-Youn Han, A. Artal-Cortes, F. Braiteh, M. Gandhi, W. Yu, C. Matheny, P. He, A. Sandler, M. Ballinger, Johan F. Vansteenkiste
- Abstract
Loading...
-
+
MS 17 - Lessons Learned from Negative Trials
- 15:45 - 17:30
- 10/17/2017
- Location: Room 303 + 304
- Type: Mini Symposium
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:V. Sriuranpong, Johan F. Vansteenkiste
-
+
MS 17.01 - PROCLAIM
15:45 - 15:55 | Presenter: Anthony Brade
- Abstract
No abstract available for this presentation
-
+
MS 17.02 - MAGRIT
15:55 - 16:05 | Presenter: Johan F. Vansteenkiste
- Abstract
Loading... -
+
MS 17.03 - Is There Such a Thing as a ‘Negative’ Trial?
16:05 - 16:30 | Presenter: Lucinda Jane Billingham
- Abstract
Loading... -
+
MS 17.04 - MET-Lung: A Phase III Trial of Onartuzumab (METMab) Plus Erlotinib vs Erlotinib in Previously Treated Stage IIIB or IV NSCLC
16:30 - 16:40 | Presenter: Karen Kelly
- Abstract
Loading... -
+
MS 17.05 - CheckMate026
16:40 - 16:50 | Presenter: David P Carbone
- Abstract
No abstract available for this presentation
-
+
MS 17.06 - Avoiding Phase II-III Attrition: Enhanced Biomarkers, Better Drugs or Improved Trial Design?
16:50 - 17:15 | Presenter: John Crowley
- Abstract
Loading... -
+
MS 17.07 - Q&A
17:15 - 17:30
- Abstract
No abstract available for this presentation